Table 2.
Univariate Cox's regression model | ||||
---|---|---|---|---|
P value | HR | 95% CI | ||
Lower | Higher | |||
Circ‐VRK1 (high vs low) | .002 | 0.375 | 0.201 | 0.700 |
Age (≥60 y vs <60 y) | .865 | 0.947 | 0.508 | 1.766 |
Pathological grade (G3 vs G1/2) | .011 | 2.846 | 1.274 | 6.354 |
Tumour size (≥3 cm vs <3 cm) | .001 | 3.363 | 1.674 | 6.755 |
T stage (T2/T3 vs T1) | .003 | 3.603 | 1.530 | 8.480 |
N stage (N1/N2/N3 vs N0) | <.001 | 3.564 | 1.817 | 6.989 |
TNM stage (III vs II/I) | <.001 | 6.496 | 3.629 | 11.626 |
ER status (positive vs negative) | .095 | 0.617 | 0.350 | 1.087 |
PR status (positive vs negative) | .175 | 0.672 | 0.378 | 1.193 |
HER2 status (positive vs negative) | .414 | 1.273 | 0.713 | 2.273 |
Data were presented as P value, HR (hazards ratio) and 95% CI (confidence interval). P < .05 was considered significant.
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; OS, overall survival; PR, progesterone receptor.